Multidrug resistance in acute myeloid leukaemia.
Multidrug resistance represents a form of pleiotropic drug resistance that has a prognostic value in untreated AML. It may affect the outcome of current chemotherapy protocols. Therefore, MDR1 expression should be systematically investigated in prospective studies. In addition, restoration of drug sensitivity may be attempted by adding drug resistance modifying agents such as cyclosporins to standard chemotherapy. The clinical value of such an approach has to be established in currently ongoing phase III studies.
Sonneveld
P
P
Department of Haematology, University Hospital Rotterdam, Dijkzigt, The Netherlands.
D000208:Acute Disease; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D018432:Drug Resistance, Multiple / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000235:genetics; D010641:Phenotype
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D004250:DNA Topoisomerases, Type II